Endocrinology of Male Infertility: Evaluation and Treatment

 

 Buy Article Permissions and Reprints

ABSTRACT

A normal functioning reproductive endocrine system is a prerequisite for normal male fertility. Any disruption of the delicately coordinated interaction between the components of the hypothalamic-pituitary-testicular axis may lead to hypogonadism and/or infertility. The goal of the clinical evaluation is to determine if the patient has an abnormality of testosterone production or action, the etiology of the abnormality, and if hormone therapy will correct the infertility. Based on a careful history, physical examination, and evaluation of the hormones of the reproductive axis, the physician will ascertain if the patient's hypogonadism is (1) prepubertal or postpubertal in onset; (2) the result of an abnormality in the hypothalamic-pituitary axis, the testes, or the androgen receptor; or (3) associated with another underlying medical condition. This information will place the patient into one of four diagnostic categories: hypogonadotropic hypogonadism, testicular failure, 5α-reductase deficiency, or androgen resistance. Within each category are disorders with identifiable pathogenic mechanisms. Recent studies have added to these lists and have provided insights into the molecular basis and inheritance patterns of several of these endocrinopathies.

REFERENCES

• 1 Sokol R Z, Swerdloff R S. Endocrine evaluation. In: Lipshultz LI, Howards ST Infertility in the Male. Third ed. St. Louis, MO; Mosby-Year Book 1997: 10-18
  Google Scholar
• 2 Bilezikjian L M, Blountal A L, Leal A M, Donaldson C J, Fischer W H, Vale W W. Autocrine/paracrine regulation of pituitary function by activin, inhibin, and follistatin.  Mol Cell Endocrinol. 2004;  225 29-36
  CrossrefPubMedGoogle Scholar
• 3 Gillam M P, Molitch M E, Lombardi G, Colao A. Advances in the treatment of prolactinomas.  Endocr Rev. 2006;  27 485-534
  CrossrefPubMedGoogle Scholar
• 4 Wilson J D, Griffin J E, Russell D W. Steroid 5α-reductase 2 deficiency.  Endocr Rev. 1993;  14 577-593
  CrossrefPubMedGoogle Scholar
• 5 Hughes I A. Mini-review: sex differentiation.  Endocrinology. 2001;  142 3281-3287
  CrossrefPubMedGoogle Scholar
• 6 Longcope C, Sato K, McKay C, Horton R. Aromatization by splanchnic tissue in men.  J Clin Endocrinol Metab. 1984;  58 1089-1093
  PubMedGoogle Scholar
• 7 Ismail A A, Barth J H. Endocrinology of gynecomastia.  Ann Clin Biochem. 2001;  38 596-607
  CrossrefPubMedGoogle Scholar
• 8 Petersen C, Soder O. The Sertoli cell – a hormonal target and ‘super’ nurse for germ cells that determines testicular size.  Horm Res. 2006;  66 153-161
  PubMedGoogle Scholar
• 9 Holsberger D R, Cooke P S. Understanding the role of thyroid hormone in Sertoli cell development: a mechanistic hypothesis.  Cell Tissue Res. 2005;  322 133-140
  CrossrefPubMedGoogle Scholar
• 10 de Kretser D M, Buzzard J J, Okuma Y et al.. The role of activin, follistatin and inhibin in testicular physiology.  Mol Cell Endocrinol. 2004;  225 57-64
  CrossrefPubMedGoogle Scholar
• 11 Kolb B A, Stanczyk F Z, Sokol R Z. Serum inhibin B levels in males with gonadal dysfunction.  Fertil Steril. 2000;  74 234-238
  CrossrefPubMedGoogle Scholar
• 12 Tong S, Wallace E M, Burger H G. Inhibins and activins: clinical advances in reproductive medicine.  Clin Endocrinol (Oxf). 2003;  58 115-127
  CrossrefPubMedGoogle Scholar
• 13 Jarow J P, Zirkin B R. The androgen microenvironment of the human testis and hormonal control of spermatogenesis.  Ann N Y Acad Sci. 2005;  1061 208-220
  CrossrefPubMedGoogle Scholar
• 14 Bain J, Langevin R, D'Costa M, Sanders R M, Hucker S. Serum pituitary and steroid hormone levels in the adult male: one value is as good as the mean of three.  Fertil Steril. 1988;  49 123-126
  PubMedGoogle Scholar
• 15 Vermeulen A, Verdonck L, Kaufman J M. A critical evaluation of simple methods for the estimation of free testosterone in serum.  J Clin Endocrinol Metab. 1999;  84 3666-3672
  CrossrefPubMedGoogle Scholar
• 16 Wang C, Catlin D H, Demers L M, Starcevic B, Swerdloff R S. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromoatography-tandem mass spectrometry.  J Clin Endocrinol Metab. 2004;  89 534-543
  CrossrefPubMedGoogle Scholar
• 17 Handelsman D J. Update in andrology.  J Clin Endocrinol Metab. 2007;  92 4505-4511
  CrossrefPubMedGoogle Scholar
• 18 Rosner W, Auchus R J, Azziz R, Sluss P M, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement.  J Clin Endocrinol Metab. 2007;  92 405-413
  CrossrefPubMedGoogle Scholar
• 19 Carruthers M. Androgen Deficiency in the Adult Male: Causes, Diagnosis and Treatment. London, England; Taylor & Francis 2004
  Google Scholar
• 20 Harman S M, Metter E J, Tobin J D, Pearson J, Blackman M R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men.  J Clin Endocrinol Metab. 2001;  86 724-731
  CrossrefPubMedGoogle Scholar
• 21 Melmed S. Update in pituitary disease.  J Clin Endocrinol Metab. 2008;  93 331-338
  CrossrefPubMedGoogle Scholar
• 22 Trarbach E B, Baptista M TM, Garmes H M, Hackel C. Molecular analysis of KAL-1, GnRH-R, NELF and EBF2 genes in a series of Kallmann syndrome and normosmic hypogonadotropic hypogonadism patients.  J Endocrinol. 2005;  187 361-368
  CrossrefPubMedGoogle Scholar
• 23 Bhagavath B, Podolsky R H, Ozata M et al.. Clinical and molecular characterization of a large sample of patients with hypogonadotropic hypogonadism.  Fertil Steril. 2006;  85 706-713
  CrossrefPubMedGoogle Scholar
• 24 Nachtigall L B, Boepple P A, Pralong F P, Crowley Jr W F. Adult-onset idiopathic hypogonadotropic hypogonadism – a treatable form of male infertility.  N Engl J Med. 1997;  336 410-415
  CrossrefPubMedGoogle Scholar
• 25 Goldstone A P, Beales P L. Genetic obesity syndromes.  Front Horm Res. 2008;  36 37-60
  PubMedGoogle Scholar
• 26 Giltay J C, Deege M, Blankenstein R A, Kastrop P MM, Wijmenga C, Lock T TWT. Apparent primary follicle-stimulating hormone deficiency is a rare cause of treatable male infertility.  Fertil Steril. 2004;  81 693-696
  CrossrefPubMedGoogle Scholar
• 27 Bunin G R, Surawicz T S, Witman P A, Preston-Martin S, Davis F, Bruner J M. The descriptive epidemiology of craniopharyngioma.  J Neurosurg. 1998;  89 547-551
  PubMedGoogle Scholar
• 28 Karavitaki N, Cudlip S, Adams C B, Wass J A. Craniopharyngiomas.  Endocr Rev. 2006;  27 371-397
  CrossrefPubMedGoogle Scholar
• 29 Murialdo G, Tamagno G. Endocrine aspects of neurosarcoidosis.  J Endocrinol Invest. 2002;  25 650-662
  CrossrefPubMedGoogle Scholar
• 30 Courtney C H, Atkinson A B. Lewis ASCommentStCommentEndCommentBody . All patients with ‘idiopathic’ hypopituitarism should be screened for hemochromatosis.  Pituitary. 2008;  , February 13 (Epub ahead of print)
  PubMedGoogle Scholar
• 31 Bayrak A, Saadat P, Mor E, Chong L, Paulson R J, Sokol R Z. Pituitary imaging is indicated for the evaluation of hyperprolactinemia.  Fertil Steril. 2005;  84 181-185
  CrossrefPubMedGoogle Scholar
• 32 Saeger W, Lüdecke D K, Buchfelder M, Fahlbusch R, Quabbe H J, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.  Eur J Endocrinol. 2007;  156 203-216
  CrossrefPubMedGoogle Scholar
• 33 Schneider H J, Kreitschmann-Andermahr I, Ghigo E, Stalla G K, Agha A. Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review.  JAMA. 2007;  298 1429-1438
  CrossrefPubMedGoogle Scholar
• 34 Maiya B, Newcombe V, Nortje J et al.. Magnetic resonance imaging changes in the pituitary gland following acute traumatic brain injury.  Intensive Care Med. 2008;  34 468-475
  CrossrefPubMedGoogle Scholar
• 35 Spratt D I, Cox P, Orav J, Moloney J, Bigos T. Reproductive axis suppression in acute illness is related to disease severity.  J Clin Endocrinol Metab. 1993;  76 1548-1554
  CrossrefPubMedGoogle Scholar
• 36 Ding E L, Song Y, Malik V S, Li S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis.  JAMA. 2006;  295 1288-1299
  CrossrefPubMedGoogle Scholar
• 37 Goodman-Gruen D, Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women.  Diabetes Care. 2000;  23 912-918
  CrossrefPubMedGoogle Scholar
• 38 Hammoud A O, Gibson M, Peterson C M, Hamilton B D, Carrell D T. Obesity and male reproductive potential.  J Androl. 2006;  27 619-626
  CrossrefPubMedGoogle Scholar
• 39 Catlin D H, Cowan D A, de la Torre R et al.. Urinary testosterone (T) to epitestosterone (E) ratios by GC/MS. I. Initial comparison of uncorrected T/E in six international laboratories.  J Mass Spectrom. 1996;  31 397-402
  CrossrefPubMedGoogle Scholar
• 40 Stikkelbroeck N M, Otten B J, Pasic A et al.. High prevalence of testicular adrenal rest tumors, impaired spermatogenesis, and Leydig cell failure in adolescent and adult males with congenital adrenal hyperplasia.  J Clin Endocrinol Metab. 2001;  86 5721-5728
  CrossrefPubMedGoogle Scholar
• 41 Ghazi A A, Hadayegh F, Khakpour G, Azizi F, Melby J C. Bilateral testicular enlargement due to adrenal remnant in a patient with C11 hydroxylase deficiency congenital adrenal hyperplasia.  J Endocrinol Invest. 2003;  26 84-87
  PubMedGoogle Scholar
• 42 Bojesen A, Juul S, Gravholt C H. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study.  J Clin Endocrinol Metab. 2003;  88 622-626
  CrossrefPubMedGoogle Scholar
• 43 Simpson J L, de la Cruz F, Swerdloff R S et al.. Klinefelter syndrome: expanding the phenotype and identifying new research directions.  Genet Med. 2003;  5 460-468
  PubMedGoogle Scholar
• 44 Thomas N S, Hassold T J. Aberrant recombination and the origin of Klinefelter syndrome.  Hum Reprod Update. 2003;  9 309-317
  CrossrefPubMedGoogle Scholar
• 45 Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E. Klinefelter's syndrome.  Lancet. 2004;  364 273-283
  CrossrefPubMedGoogle Scholar
• 46 Kamischke A, Baumgardt A, Horst J, Nieschlag E. Clinical and diagnostic features of patients with suspected Klinefelter syndrome.  J Androl. 2003;  24 41-48
  PubMedGoogle Scholar
• 47 Vernaeve V, Staessen C, Verheyen G, Van Steirteghem A, Devroey P, Tournaye H. Can biological or clinical parameters predict testicular sperm recovery in 47,XXY Klinefelter's syndrome patients?.  Hum Reprod. 2004;  19 1135-1139
  CrossrefPubMedGoogle Scholar
• 48 Bojesen A, Juul S, Birkebaek N H, Gravholt C H. Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses.  J Clin Endocrinol Metab. 2006;  91 1254-1260
  CrossrefPubMedGoogle Scholar
• 49 Swerdlow A J, Hermon C, Jacobs P A et al.. Mortality and cancer incidence in persons with numerical sex chromosome abnormalities: a cohort study.  Ann Hum Genet. 2001;  65 177-188
  CrossrefPubMedGoogle Scholar
• 50 Geschwind D H, Boone K B, Miller B L, Swerdloff R S. Neurobehavioral phenotype of Klinefelter syndrome.  Ment Retard Dev Disabil Res Rev. 2000;  6 107-116
  CrossrefPubMedGoogle Scholar
• 51 Ross J L, Roeltgen D P, Stefanatos G et al.. Cognitive and motor development during childhood in boys with Klinefelter syndrome.  Am J Med Genet A. 2008;  146A 708-719
  PubMedGoogle Scholar
• 52 Hasle H, Mellemgaard A, Nielsen J, Hansen J. Cancer incidence in men with Klinefelter syndrome.  Br J Cancer. 1995;  71 416-420
  PubMedGoogle Scholar
• 53 Hultborn R, Hanson C, Köpf I, Verbiené I, Warnhammar E, Weimarck A. Prevalence of Klinefelter's syndrome in male breast cancer patients.  Anticancer Res. 1997;  17 4293-4297
  PubMedGoogle Scholar
• 54 Lue Y, Jentsch J D, Wang C et al.. XXY mice exhibit gonadal and behavioral phenotypes similar to Klinefelter syndrome.  Endocrinology. 2005;  146 4148-4154
  CrossrefPubMedGoogle Scholar
• 55 Meschede D, Horst J. The molecular genetics of male infertility.  Mol Hum Reprod. 1997;  3 419-430
  CrossrefPubMedGoogle Scholar
• 56 Cilento B G, Atala A. Cryptorchidism, testicular torsion, and torsion of testicular appendages. In: Kandeel FR Male Reproductive Dysfunction: Pathophysiology and Treatment. New York, NY, and London, England; Informa Healthcare 2007: 161-171
  Google Scholar
• 57 Hauser R, Sokol R. Science linking environmental contaminant exposures with fertility and reproductive health impacts in the adult male.  Fertil Steril. 2008;  89(Suppl 1) e59-e65
  CrossrefPubMedGoogle Scholar
• 58 Marchetti F, Wyrobek A J. Mechanisms and consequences of paternally-transmitted chromosomal abnormalities.  Birth Defects Res C Embryo Today. 2005;  75 112-129
  CrossrefPubMedGoogle Scholar
• 59 Dowsing A T, Yong E L, Clark M, McLachlan R I, de Kretser D M, Trounson A O. Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene.  Lancet. 1999;  354 640-643
  CrossrefPubMedGoogle Scholar
• 60 Griffin J E. Androgen resistance – the clinical and molecular spectrum.  N Engl J Med. 1992;  326 611-618
  PubMedGoogle Scholar
• 61 Davis-Dao C A, Tuazon E D, Sokol R Z, Cortessis V K. J Clin Endocrinol Metab. 2007;  92 4319-4326
  CrossrefPubMed
• 62 Finkel D M, Phillips J L, Snyder P J. Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism.  N Engl J Med. 1985;  313 651-655
  CrossrefPubMedGoogle Scholar
• 63 Sokol R Z. Male factor infertility. In: Lobo RA, Mishell DR Jr, Paulson RJ, Shoupe D Infertility, Contraception, and Reproductive Endocrinology. Fourth ed. Malden, MA; Blackwell Science 1997: 547-566
  Google Scholar
• 64 Bouloux P M, Nieschlag E, Burger H G et al.. Induction of spermatogenesis by recombinant follicle-stimulating hormone (puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotropin alone.  J Androl. 2003;  24 604-611
  PubMedGoogle Scholar
• 65 Bouloux P, Warne D W, Loumaye E, Study F SH. Group in Men's Infertility. Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism.  Fertil Steril. 2002;  77 270-273
  CrossrefPubMedGoogle Scholar
• 66 Attia A M, Al-Inany H G, Proctor M L. Gonadotrophins for idiopathic male factor subfertility.  Cochrane Database Syst Rev. 2006;  1 CD005071
  PubMedGoogle Scholar
• 67 Fukagai T, Kurosawa K, Sudo N et al.. Bilateral testicular tumors in an infertile man previously treated with follicle-stimulating hormones.  Urology. 2005;  65 592.e16-592.e18
  PubMedGoogle Scholar
• 68 Liu P Y, Handelsman D J. The present and future state of hormonal treatment for male infertility.  Hum Reprod Update. 2003;  9 9-23
  CrossrefPubMedGoogle Scholar
• 69 Liu P Y, Turner L, Rushford D, McDonald J, Baker H W, Conway A J. Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men.  Hum Reprod. 1999;  14 1540-1545
  CrossrefPubMedGoogle Scholar
• 70 Sokol R Z, McClure R D, Peterson M, Swerdloff R S. Gonadotropin therapy failure secondary to human chorionic gonadotropin-induced antibodies.  J Clin Endocrinol Metab. 1981;  52 929-932
  PubMedGoogle Scholar
• 71 Whitten S J, Nangia A K, Kolettis P N. Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate.  Fertil Steril. 2006;  86 1664-1668
  CrossrefPubMedGoogle Scholar
• 72 Hoffman A R, Crowley Jr W F. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone.  N Engl J Med. 1982;  307 1237-1241
  PubMedGoogle Scholar
• 73 Kliesch S, Behre H M, Nieschlag E. High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men.  Eur J Endocrinol. 1994;  131 347-354
  PubMedGoogle Scholar
• 74 Skarin G, Nillius S J, Wibell L, Wide L. Chronic pulsatile low dose GnRH therapy for induction of testosterone production and spermatogenesis in a man with secondary hypogonadotropic hypogonadism.  J Clin Endocrinol Metab. 1982;  55 723-726
  PubMedGoogle Scholar
• 75 Hammar M, Berg A A. Long term androgen replacement therapy does not preclude gonadotrophin-induced improvement on spermatogenesis.  Scand J Urol Nephrol. 1990;  24 17-19
  PubMedGoogle Scholar
• 76 Ley S B, Leonard J M. Male hypogonadotropic hypogonadism. Factors influencing response to human chorionic gonadotropin and human menopausal gonadotropin, including prior endogenous androgens.  J Clin Endocrinol Metab. 1985;  61 746-752
  PubMedGoogle Scholar
• 77 Schiff J D, Palermo G D, Veeck L L, Goldstein M, Rosenwaks Z, Schlegel P N. Success of testicular sperm injection and intracytoplasmic sperm injection in men with Klinefelter syndrome.  J Clin Endocrinol Metab. 2005;  90 6263-6267
  CrossrefPubMedGoogle Scholar
• 78 Zitzmann M, Nordhoff V, von Schönfeld V et al.. Elevated follicle-stimulating hormone levels and the chances for azoospermic men to become fathers after retrieval of elongated spermatids from cryopreserved testicular tissue.  Fertil Steril. 2006;  86 339-347
  CrossrefPubMedGoogle Scholar
• 79 Foresta C, Bettella A, Garolla A, Ambrosini G, Ferlin A. Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study.  Fertil Steril. 2005;  84 654-661
  CrossrefPubMedGoogle Scholar
• 80 Hauser R, Temple-Smith P D, Southwick G J, de Kretser D. Fertility in cases of hypergonadotropic azoospermia.  Fertil Steril. 1995;  63 631-636
  PubMedGoogle Scholar
• 81 Pavlovich C P, King P, Goldstein M, Schlegel P N. Evidence of a treatable endocrinopathy in infertile men.  J Urol. 2001;  165 837-841
  CrossrefPubMedGoogle Scholar
• 82 Raman J D, Schlegel P N. Aromatase inhibitors for male infertility.  J Urol. 2002;  167 624-629
  CrossrefPubMedGoogle Scholar
• 83 Sokol R Z, Palacios A, Campfield L A, Saul C, Swerdloff R S. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men.  Fertil Steril. 1982;  37 425-430
  PubMedGoogle Scholar
• 84 Meikle A W, Arver S, Dobs A S, Sanders S W, Rajaram L, Mazer N A. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site – a clinical research center study.  J Clin Endocrinol Metab. 1996;  81 1832-1840
  CrossrefPubMedGoogle Scholar
• 85 Swerdloff R S, Wang C, Cunningham G et al.. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.  J Clin Endocrinol Metab. 2000;  85 4500-4510
  CrossrefPubMedGoogle Scholar

Rebecca Z SokolM.D. M.P.H. 

Women's and Children's Hospital, 1240 North Mission Road

Room 8K3, Los Angeles, CA 90033

Email: rsokol@usc.edu